IVDMD Classification Under TR-006: Classes A to D Explained

1. Key takeaways

In vitro diagnostic medical devices (IVDMD) are classified separately, under technical reference document TR-006, Classification of In Vitro Diagnostic Medical Devices, into 4 classes: A, B, C and D. The listing scope covers only classes B, C and D; class A is outside it. Unlike general medical devices, which are classified by invasiveness and duration of contact, IVDMD classification turns on the risk consequence of the test purpose: whether the test is used for screening, whether it serves blood safety, and whether an erroneous result causes serious consequences. Self-testing products are frequently under-classified, and that is where classification errors cluster.

The distinction matters commercially because the class fixes both eligibility for listing and the depth of performance evidence. An IVD placed one class too low is not a device with a lighter file; it is a device that cannot be listed at all, and the error surfaces at the point where a distributor or a hospital asks for a listing number.

The GRZAN view. IVD classification is decided by the claim on the box, not by the platform inside it, so the intended use statement is the first document to get right.

2. Legal basis

Rules and documentation. TR-006 sets the classification rules for IVDMD in full. GN-06 sets the documentation required to list a Class B, C or D IVD, including the list of marketing approvals from reference jurisdictions. TR-003 is used only for comparison, since the two rule sets are not interchangeable. The MDACS scheme page provides worked classification examples for IVDMD, and the MDD overview uploaded on 8 October 2025 restates the coverage of the scheme and the device categories within it.

Thematic pages resolve common cases. MDD maintains dedicated pages for household blood glucose meters and strips, rapid antigen tests for influenza and rapid antigen tests for COVID-19, each stating the classification applied. Those pages are the fastest way to test an internal assumption before a determination is written.

3. Expert insights

Two classification systems, no cross-over. GMD rules work on physical dimensions: invasiveness, duration of contact, energy supply. IVDMD rules work on purpose and consequence: what the test is for and what happens if the answer is wrong. A manufacturer filing both device types cannot apply one set of habits to the other, and the IVD file should be determined by someone who works from TR-006 rather than from TR-003 by analogy.

Self-test products usually sit higher than intuition suggests. Household blood glucose meters and strips, rapid influenza antigen tests and COVID-19 rapid antigen tests all have dedicated MDD pages stating their classification. The reasoning is the consequence dimension: an incorrect self-test result can delay care or produce wrong handling at home, and that possibility alone pushes the class upward. Companies that reason from the simplicity of the device rather than from the consequence of an error routinely land one class too low.

Performance evaluation replaces clinical evaluation. A general medical device file includes a clinical evaluation report. An IVD file includes a performance evaluation report. The evidence structures differ: the former weighs clinical benefit against risk, the latter combines analytical performance with clinical performance. Substituting one for the other is a common and avoidable deficiency, and it is expensive because it is discovered late.

Class sets the documentation burden as well as eligibility. GN-06 requirements are applied according to class, so an IVD placed one class above what the rules produce pays in evidence volume, while one placed a class below loses the route altogether. The only defensible target is the class the rules actually yield, documented well enough to explain itself to a reviewer who was not involved in the decision.

Blood screening sits at the top of the scale. Products used for donor screening, blood grouping or nucleic acid testing of pathogens usually land in the highest class, because an erroneous result has wide reach. This is a practical estimate, and the class should still be determined item by item against the rules in TR-006 rather than assumed from the category.

4. Practical recommendations

• Classify by intended use, not by technology platform. Immunochromatography, chemiluminescence and molecular testing are platforms; the class follows what the test is for.
• Establish self-test status first. Self-testing, including household use, changes the classification inputs, so the user population must be stated explicitly in the instructions.
• Match the reference approval to the risk class. The notes to the expedited listing scheme require reference jurisdiction approvals to carry an appropriate risk classification, and an approval at a different class may not be accepted.
• Check the thematic pages before drafting. Where a product corresponds to one of the MDD thematic pages, compare against the official example first and record the comparison.
• Commission the performance evaluation early. Analytical and clinical performance evidence takes longer to assemble than a clinical evaluation borrowed from a device file.

5. Verification checklist

• □ IVDMD classification determined under TR-006 with the reasoning recorded.
• □ Official in vitro diagnostic medical device classification programme used and output retained.
• □ Self-test or household use status confirmed.
• □ Class confirmed as B, C or D, that is, within the listing scope.
• □ Risk classification in the reference jurisdiction approval consistent with the Hong Kong, China determination.
• □ Performance evaluation report prepared rather than a clinical evaluation report.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages Medical Device Administrative Control System (MDACS) listings, coordinates import licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com